Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System
December 09 2019 - 8:05AM
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or
the “Company”), a clinical-stage drug development company
pioneering transformative medicines that target the endocannabinoid
system, today announced that it will host a symposium on the
endocannabinoid system (“ECS”) and the therapeutic potential of
targeting the ECS. The symposium will be webcasted live (details
below) on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET.
Yuval Cohen, Ph.D., Chief Executive Officer of
Corbus, will host the event, and Barbara White, M.D., Chief Medical
Officer and Head of Research of Corbus will moderate the panel
session. The panel session will feature presentations from the
following experts:
|
● |
The ECS and resolution of inflammation; |
|
|
Charles N. Serhan, Ph.D., DSc, First Endowed Distinguished
Scientist, Brigham and Woman’s Hospital, currently serving as
Director of the Center for Experimental Therapeutics and
Reperfusion Injury at Brigham and Women’s Hospital. Simon Gelman
Professor of Anesthesia (Biochemistry and Molecular Pharmacology)
at Harvard Medical School, Professor of Oral Medicine, Infection
and Immunity at Harvard School of Dental Medicine |
|
|
|
|
● |
The ECS and skin inflammation; |
|
|
Adam Friedman, M.D., FAAD, Interim Chair, Department of Dermatology
and Professor of Dermatology, George Washington University School
of Medicine and Health Sciences |
|
|
|
|
● |
Potential applicability of targeting the ECS to treat autoimmune
diseases: Lenabasum in systemic sclerosis; |
|
|
Jessica Gordon, M.D., Associate Professor of Medicine, Weill
Cornell Medical College, Associate Attending in the Department of
Rheumatology at the Hospital for Special Surgery in New York |
Webcast Details
Interested participants may dial into the event
using (877) 407-3978 (domestic) or (412) 902-0039 (international),
or can access the live video webcast and accompanying slide
presentation on the Events page of the Investors section of the
Corbus website, www.corbuspharma.com. The webcast replay will be
archived for 90 days following the event. About
Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase
3 clinical-stage pharmaceutical company focused on the development
and commercialization of novel therapeutics to treat inflammatory
and fibrotic diseases by leveraging its pipeline of rationally
designed, endocannabinoid system-targeting drug candidates. The
Company's lead product candidate, lenabasum, is a novel, oral,
selective cannabinoid receptor type 2 (CB2) agonist rationally
designed to resolve chronic inflammation and fibrotic processes.
Lenabasum is currently being evaluated in systemic sclerosis,
cystic fibrosis, dermatomyositis and systemic lupus
erythematosus.
Corbus is also developing a pipeline of drug
candidates targeting the endocannabinoid system. The pipeline
includes CRB-4001, a 2nd generation, selective cannabinoid receptor
type 1 (CB1) inverse agonist designed to be peripherally
restricted. Potential indications for CRB-4001 include nonalcoholic
steatohepatitis (NASH), among others. Corbus expects data from a
CRB-4001 Phase 1 safety study in 2020.
For more information, please visit
www.CorbusPharma.com and connect with the Company on Twitter,
LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Corbus Pharmaceuticals Contacts:
Ted Jenkins, Senior Director, Investor Relations and Corporate
CommunicationsPhone: +1 (617) 415-7745Email:
ir@corbuspharma.com
Lindsey Smith, Associate Director, Investor Relations and
Corporate CommunicationsPhone: +1 (617) 415-7749Email:
mediainfo@corbuspharma.com
Jenene ThomasJenene Thomas Communications, LLCPhone: +1 (833)
475-8247Email: crbp@jtcir.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Sep 2023 to Sep 2024